Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
LEARN ABOUT OUR TECHNOLOGY
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.
Our gene therapy pipeline promises the hope of cures for vision disorders.
Nanoscope News & Events
-
14 Emerging Tech Trends for 2021—and Dallas-Area Companies That Are Innovating for the FutureMarch 7, 2021 -
Nanoscope's Optical Gene Therapies to be Featured at Optogenetics and Optical Manipulation 2021 ConferenceMarch 5, 2021 -
Nanoscope President to Deliver Talk on Gene Therapy for Retinal Diseases at Association for Ocular Pharmacology and Therapeutics ConferenceMarch 3, 2021 -
Nature: Light-activated genetic therapy to treat blindness enters clinicFebruary 9, 2021
-
Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of HealthFebruary 2, 2021
